Kyle Mikson
Stock Analyst at Canaccord Genuity
(0.25)
# 3,227
Out of 4,412 analysts
42
Total ratings
10.53%
Success rate
-37.28%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLK Olink Holding AB (publ) | Reiterates: Hold | $26 | $22.84 | +13.84% | 2 | Mar 26, 2024 | |
| AKYA Akoya Biosciences | Reiterates: Buy | $10 | $3.80 | +163.16% | 1 | Mar 5, 2024 | |
| BDSX Biodesix | Reiterates: Buy | $3.5 | $1.24 | +183.40% | 2 | Mar 4, 2024 | |
| NTRA Natera | Maintains: Buy | $87 → $100 | $91.66 | +9.10% | 1 | Feb 29, 2024 | |
| GH Guardant Health | Maintains: Buy | $50 → $45 | $17.35 | +159.37% | 2 | Feb 23, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $100 → $90 | $58.85 | +52.93% | 5 | Feb 22, 2024 | |
| ILMN Illumina | Downgrades: Hold | $210 → $120 | $122.28 | -1.86% | 5 | Nov 10, 2023 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $17 → $15 | $1.47 | +920.41% | 5 | Oct 31, 2023 | |
| QSI Quantum-Si incorporated | Downgrades: Hold | $3.5 → $2 | $1.65 | +21.21% | 2 | Sep 25, 2023 | |
| QTRX Quanterix | Upgrades: Buy | $25 → $32 | $15.56 | +105.66% | 3 | Sep 25, 2023 | |
| TXG 10x Genomics | Reiterates: Buy | $70 | $27.59 | +153.72% | 3 | Sep 19, 2023 | |
| VNRX VolitionRx | Maintains: Overweight | $3 → $2 | $0.91 | +118.89% | 2 | Aug 16, 2023 | |
| CSTL Castle Biosciences | Maintains: Buy | $60 → $40 | $20.34 | +96.66% | 2 | Jun 6, 2023 | |
| XGN Exagen | Maintains: Buy | $8 → $7 | $1.41 | +395.72% | 1 | Nov 15, 2022 | |
| TTOO T2 Biosystems | Downgrades: Hold | $1,250 → $250 | $2.84 | +8,702.82% | 1 | Oct 14, 2022 | |
| LUCD Lucid Diagnostics | Maintains: Buy | $18 → $12 | $0.68 | +1,656.70% | 2 | Mar 29, 2022 | |
| PAVM PAVmed | Initiates: Overweight | $49 | $1.72 | +2,760.47% | 1 | Mar 30, 2021 | |
| ICAD iCAD, Inc. | Initiates: Overweight | n/a | $1.47 | - | 1 | Jan 29, 2021 | |
| AWH Aspira Women's Health | Initiates: Overweight | n/a | $3.33 | - | 1 | Jan 29, 2021 |
Olink Holding AB (publ)
Mar 26, 2024
Reiterates: Hold
Price Target: $26
Current: $22.84
Upside: +13.84%
Akoya Biosciences
Mar 5, 2024
Reiterates: Buy
Price Target: $10
Current: $3.80
Upside: +163.16%
Biodesix
Mar 4, 2024
Reiterates: Buy
Price Target: $3.5
Current: $1.24
Upside: +183.40%
Natera
Feb 29, 2024
Maintains: Buy
Price Target: $87 → $100
Current: $91.66
Upside: +9.10%
Guardant Health
Feb 23, 2024
Maintains: Buy
Price Target: $50 → $45
Current: $17.35
Upside: +159.37%
Exact Sciences
Feb 22, 2024
Maintains: Buy
Price Target: $100 → $90
Current: $58.85
Upside: +52.93%
Illumina
Nov 10, 2023
Downgrades: Hold
Price Target: $210 → $120
Current: $122.28
Upside: -1.86%
Pacific Biosciences of California
Oct 31, 2023
Maintains: Buy
Price Target: $17 → $15
Current: $1.47
Upside: +920.41%
Quantum-Si incorporated
Sep 25, 2023
Downgrades: Hold
Price Target: $3.5 → $2
Current: $1.65
Upside: +21.21%
Quanterix
Sep 25, 2023
Upgrades: Buy
Price Target: $25 → $32
Current: $15.56
Upside: +105.66%
10x Genomics
Sep 19, 2023
Reiterates: Buy
Price Target: $70
Current: $27.59
Upside: +153.72%
VolitionRx
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.91
Upside: +118.89%
Castle Biosciences
Jun 6, 2023
Maintains: Buy
Price Target: $60 → $40
Current: $20.34
Upside: +96.66%
Exagen
Nov 15, 2022
Maintains: Buy
Price Target: $8 → $7
Current: $1.41
Upside: +395.72%
T2 Biosystems
Oct 14, 2022
Downgrades: Hold
Price Target: $1,250 → $250
Current: $2.84
Upside: +8,702.82%
Lucid Diagnostics
Mar 29, 2022
Maintains: Buy
Price Target: $18 → $12
Current: $0.68
Upside: +1,656.70%
PAVmed
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $1.72
Upside: +2,760.47%
iCAD, Inc.
Jan 29, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.47
Upside: -
Aspira Women's Health
Jan 29, 2021
Initiates: Overweight
Price Target: n/a
Current: $3.33
Upside: -